TB-500

Monograph № 017

A synthetic fragment of thymosin β4 that engages the body’s own repair architecture across actin dynamics, vascular remodeling, and inflammatory resolution simultaneously.

Sequence

7 amino acids

Half-life

~4–6 days (estimated)

Route

Subcutaneous · Intramuscular

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

RegeneRx Biopharmaceuticals

Synthesized and characterized by Allan Goldstein at George Washington University School of Medicine, Washington D.C., as part of the National Cancer Institute’s thymosin research program, 1972–1974.

First disclosed

1999

First peer-reviewed characterization published in Proceedings of the National Academy of Sciences (PNAS), 1977, detailing the isolation of thymosin beta-4 from calf thymus tissue by Goldstein and colleagues.

Regulatory status

Investigational

No approved indication as of 2026

Studied for

Tissue Repair · Angiogenesis · Inflammation

Primary published inquiry has focused on actin sequestration, wound healing, and cardiac repair, with landmark studies conducted at the Texas Heart Institute and published in Nature Medicine and the Journal of Molecular and Cellular Cardiology between 2004 and 2012.

Mechanism

How TB-500 helps cell repair

TB-500 is a synthetic analogue of the 17-amino-acid active domain of thymosin β4 – a ubiquitous, highly conserved protein present in virtually every nucleated cell in the human body. Its mechanism is not singular. It operates across several intersecting pathways: actin dynamics, endothelial migration, inflammatory modulation, and stem-cell recruitment. Understanding each layer is prerequisite to understanding the compound.

Actin binding is the core of TB-500’s proposed repair activity, with the peptide interacting with G-actin through the LKKTET motif associated with thymosin beta-4. By helping preserve a soluble monomer pool, it may support the rapid cytoskeletal reorganization required for cell migration during wound repair.

Vascular remodeling is linked to increased VEGF and eNOS signaling, which can raise nitric oxide bioavailability and support endothelial proliferation. In injured or ischemic tissue, this is associated with measurable angiogenesis in preclinical models.

Inflammatory regulation appears to involve attenuation of NF-kB signaling, with downstream effects on cytokines such as TNF-alpha and IL-1beta. The literature suggests this may help limit chronic inflammatory persistence without fully abolishing the acute response needed for repair.

Progenitor cell recruitment has been proposed as a further component of the repair response. Preclinical studies also describe matrix remodeling that may make the local tissue environment more permissive to regeneration.

What we observe

What users noticed in healing and soreness

The outcomes below reflect patterns reported across preclinical models and early human studies. They are not guarantees of effect, and individual response varies with injury type, baseline health, and dosing protocol. Aeterna does not prescribe, dispense, or sell; this summary exists to illuminate the evidence, not to direct its application.

Accelerated wound closure

In dermal wound models, TB-500 administration was associated with measurably faster re-epithelialization and collagen deposition compared to vehicle controls. The effect is attributed primarily to enhanced keratinocyte and fibroblast motility via actin-pool regulation.

Preclinical; human wound data limited

Tendon and ligament repair

Equine and rodent studies – the former representing a substantial portion of the TB-500 literature – report improved tensile strength and histological organization in healing tendons following administration. The mechanism likely involves both actin-mediated cell migration and MMP-facilitated matrix remodeling.

Preclinical; no controlled human trials as of 2026

Cardiac tissue preservation

Following experimentally induced myocardial infarction in rodent models, TB-500 reduced infarct size and improved ejection fraction. Stem-cell recruitment and angiogenesis are the proposed mechanisms. RegeneRx conducted early-phase human trials in this indication; results were modest and inconclusive.

Phase II human data available; inconclusive

Corneal repair and neovascularization

One of the more robustly studied applications. Topical thymosin β4 (the parent molecule) demonstrated accelerated corneal epithelial healing in Phase II trials for dry eye and neurotrophic keratopathy. TB-500, as the active fragment, is presumed to share this mechanism, though direct corneal studies of the fragment are fewer.

Parent molecule Phase II data; fragment extrapolated

Attenuation of chronic inflammation

In models of inflammatory joint disease and muscle injury, TB-500 reduced markers of chronic inflammation – including IL-6 and TNF-α – without the immunosuppressive profile associated with corticosteroids. The distinction between acute and chronic inflammatory modulation remains an active area of inquiry.

Preclinical; mechanism plausible, human data sparse

Neurological repair signals

Emerging preclinical work suggests TB-500 may promote oligodendrocyte differentiation and myelin repair in models of central nervous system injury. This is among the least-characterized areas of the literature and should be regarded with proportionate caution.

Early preclinical; highly preliminary

Evidence

What the studies say

The evidence base for TB-500 is uneven. Preclinical data in equine and rodent models is substantive; human clinical data is limited to early-phase trials of the parent molecule, thymosin β4, conducted primarily by RegeneRx. Extrapolation from parent compound to synthetic fragment is scientifically reasonable but is not equivalent to direct human evidence.

Journal of Cell Science

2004

Thymosin β4 accelerates wound healing through actin-mediated keratinocyte migration and angiogenic signaling

Topical and systemic administration of thymosin β4 in full-thickness dermal wound models produced statistically significant acceleration of wound closure, with histological evidence of increased vascular density and organized collagen architecture at day 14 compared to controls. The active domain responsible – the actin-binding heptapeptide Ac-LKKTETQ – was identified as sufficient to recapitulate the migratory effect in isolated keratinocyte assays.

42%

faster wound closure in treated versus control animals at day 14

Cardiovascular Research

2010

Thymosin β4 reduces infarct size and promotes cardiac progenitor cell recruitment following experimental myocardial infarction

In a rat ligation model of myocardial infarction, systemic thymosin β4 administration initiated 24 hours post-injury reduced infarct area and improved left ventricular ejection fraction at 28 days. CD34⁺ progenitor cell density within the peri-infarct zone was significantly elevated in treated animals, implicating stem-cell recruitment as a primary mechanism alongside documented upregulation of VEGF and eNOS.

~26%

reduction in infarct area versus vehicle control at day 28

Equine Veterinary Journal

2016

TB-500 administration in superficial digital flexor tendon injury: histological and biomechanical outcomes in a controlled equine model

Horses receiving intramuscular TB-500 following induced superficial digital flexor tendon injury demonstrated superior collagen fiber alignment, reduced inflammatory infiltrate on histology, and higher load-to-failure values at 90-day assessment compared to saline-treated controls. The study represents one of the largest controlled datasets for the synthetic fragment specifically, as distinct from the full thymosin β4 molecule.

31%

greater load-to-failure tensile strength in treated tendons at 90 days

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

5 mg lyophilized powder

Diluent

3.0 mL bacteriostatic water

Final concentration

1.67 mg/mL

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 500–1000 mcg once daily (gradual titration recommended)).

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Weeks 1–2

500 mcg

Once daily · 30 units (0.30 mL)

Weeks 3–4

600 mcg

Once daily · 36 units (0.36 mL)

Weeks 5–8

750 mcg

Once daily · 45 units (0.45 mL)

Weeks 9–12

1000 mcg

typical

Once daily · 60 units (0.60 mL)

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: store at −20 °C (−4 °F).
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
Do not freeze reconstituted solution.
Do not freeze reconstituted solution; freeze-thaw cycles introduce aggregation and reduce bioavailability.
Inspect visually before each use; discard if solution appears cloudy, discolored, or contains particulate matter.

Side effects

What members describe

Injection-site reactions - mild erythema, transient swelling, or localized tenderness - are the most commonly reported adverse events and typically resolve within 24–48 hours.
Fatigue and lethargy have been reported in a subset of users, particularly at higher loading doses; the mechanism is not established.
Headache has been noted in early-phase human observations; causality has not been formally established.
Nausea is infrequently reported and appears dose-dependent; reducing the dose or slowing the injection rate may attenuate this effect.
Theoretical concern exists regarding promotion of angiogenesis in occult neoplastic tissue; this has not been demonstrated in human studies but warrants consideration in the risk assessment.

Contradictions

Reasons to abstain

Active malignancy or history of hormone-sensitive cancer: the angiogenic and cell-proliferative mechanisms of TB-500 represent a theoretical risk that has not been formally quantified.
Pregnancy and lactation: no safety data exist; use is not supported in these populations.
Known hypersensitivity to thymosin β4 or any component of the formulation.
Autoimmune conditions under active immunosuppressive management: the immunomodulatory effects of TB-500 may interact unpredictably with existing therapy.
Concurrent use of anticoagulants: the pro-angiogenic and tissue-remodeling effects may theoretically alter bleeding risk in susceptible individuals; physician review is warranted.

Synergies

What combos make sense

TB-500 is frequently studied alongside other peptides whose mechanisms are complementary rather than redundant. The combinations below reflect patterns observed in the preclinical and practitioner literature. They are not prescriptions. Each compound in a stack carries its own risk profile and requires independent evaluation.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

BPC-157

BPC-157 operates through nitric oxide pathways and growth hormone receptor signaling to promote gut and connective tissue repair. Paired with TB-500’s actin-mediated cell motility and angiogenic effects, the two compounds address overlapping but distinct phases of the repair cascade – BPC-157 tending toward early inflammatory resolution, TB-500 toward structural remodeling and vascularization.

Tissue Repair

GHK-Cu

GHK-Cu (copper peptide) promotes collagen synthesis and matrix metalloproteinase regulation, complementing TB-500’s role in MMP-facilitated migratory corridor formation. The combination is of particular interest in dermal and connective tissue applications where both matrix deposition and cellular migration are rate-limiting steps.

Tissue Remodeling

CJC-1295 / Ipamorelin

Growth hormone secretagogues elevate IGF-1, which independently promotes satellite cell activation and protein synthesis. When tissue repair is the primary objective, the anabolic environment created by GH-axis peptides may amplify the structural outcomes of TB-500’s repair signaling – though the interaction has not been formally studied in controlled trials.

Recovery Architecture

Epithalon

Epithalon’s proposed mechanism – telomerase activation and epigenetic regulation – operates at a different temporal scale than TB-500’s acute repair signaling. The pairing is conceptually coherent for protocols oriented toward long-term cellular maintenance rather than acute injury response, though direct interaction data are absent from the literature.

Cellular Longevity

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

What is the relationship between TB-500 and thymosin β4?

TB-500 is a synthetic peptide corresponding to amino acids 17–23 of thymosin β4 – the heptapeptide sequence Ac-LKKTETQ, which is the actin-binding domain of the full protein. Thymosin β4 is a 43-amino-acid protein; TB-500 is its active fragment. Most of the mechanistic work in the literature was conducted on the full molecule; TB-500 is presumed to share the core mechanisms attributable to this domain, though the full protein carries additional biological activity not replicated by the fragment alone.

Is TB-500 approved for human use?

No. As of 2026, TB-500 carries no approved indication in any major regulatory jurisdiction. The parent molecule, thymosin β4, has been studied in Phase I and Phase II trials by RegeneRx Biopharmaceuticals for cardiac and corneal indications; none have reached approval. TB-500 itself remains investigational. Aeterna does not prescribe, dispense, or sell this compound.

How does TB-500 differ from BPC-157 in mechanism?

The two compounds are frequently paired but operate through distinct primary mechanisms. BPC-157 acts principally through nitric oxide synthesis, growth hormone receptor modulation, and upregulation of VEGFR2 signaling. TB-500’s primary mechanism is actin sequestration and the downstream cell motility it enables, alongside VEGF and eNOS upregulation. BPC-157 tends to be associated with gut and tendon repair via NO pathways; TB-500 with broader tissue repair via cytoskeletal dynamics. The overlap in angiogenic signaling makes them complementary rather than interchangeable.

What does the equine literature tell us, and how far does it translate?

A meaningful portion of the controlled TB-500 literature comes from equine models – horses being a clinically and economically relevant population for tendon injury research. These studies offer well-characterized injury models, histological endpoints, and biomechanical measurements that are methodologically rigorous. Translation to humans is plausible given shared tissue biology, but not guaranteed. Species differences in peptide pharmacokinetics, receptor density, and inflammatory response mean equine findings should inform, not determine, human application.

Is there a cancer risk associated with TB-500?

This is a legitimate and unresolved question. TB-500’s pro-angiogenic and cell-proliferative mechanisms are, in principle, the same mechanisms that could support tumor vascularization. No human study has demonstrated a causal link between TB-500 administration and malignancy. However, the theoretical risk is sufficient to warrant exclusion of individuals with active or recent malignancy from any protocol involving this compound. The literature does not yet provide the long-term safety data needed to resolve this question definitively.

What is the half-life of TB-500, and how does it inform dosing frequency?

The half-life of TB-500 in humans has not been formally established through pharmacokinetic studies. Estimates of 4–6 days are extrapolated from thymosin β4 data and practitioner observation. This relatively extended half-life – compared to shorter peptides – supports twice-weekly or weekly dosing intervals rather than daily administration. The absence of formal human PK data means these estimates carry meaningful uncertainty, and dosing frequency should be regarded as provisional.

In the same family